{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:10:02Z","timestamp":1760116202094,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"EU FP7 project TRANSVAC","doi-asserted-by":"publisher","award":["FP7-INFRASTRUCTURES-2008-228403","730964","101046133"],"award-info":[{"award-number":["FP7-INFRASTRUCTURES-2008-228403","730964","101046133"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union\u2019s Horizon 2020 research and innovation program","doi-asserted-by":"publisher","award":["FP7-INFRASTRUCTURES-2008-228403","730964","101046133"],"award-info":[{"award-number":["FP7-INFRASTRUCTURES-2008-228403","730964","101046133"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union\u2019s Horizon Europe research and innovation program","doi-asserted-by":"publisher","award":["FP7-INFRASTRUCTURES-2008-228403","730964","101046133"],"award-info":[{"award-number":["FP7-INFRASTRUCTURES-2008-228403","730964","101046133"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine community since 2009 including contributing toward the development and optimization of vaccine candidates as well as the provision of new adjuvants, research protocols, and technologies. Scientific services were provided in support of 88 different vaccine development projects, and 400 professionals attended TRANSVAC training events on various vaccine-related topics. Here, we review the accomplishments of the TRANSVAC consortia and analyze the continued needs of academic and industrial vaccine developers in Europe. The findings highlight the benefits of coordination across different sectors, both through research infrastructures such as TRANSVAC and other mechanisms, to address the current and future global health challenges and ensure that European vaccine developers have the support required to successfully compete in the global market.<\/jats:p>","DOI":"10.3390\/vaccines12121446","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T04:33:29Z","timestamp":1734928409000},"page":"1446","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Boosting Vaccine Research: The 16-Year Journey of TRANSVAC Vaccine Infrastructure"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4839-1752","authenticated-orcid":false,"given":"William","family":"Martin","sequence":"first","affiliation":[{"name":"European Vaccine Initiative (EVI), 69115 Heidelberg, Germany"}]},{"given":"Catarina","family":"Lu\u00eds","sequence":"additional","affiliation":[{"name":"European Vaccine Initiative (EVI), 69115 Heidelberg, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8728-5410","authenticated-orcid":false,"given":"Stefan","family":"Jungbluth","sequence":"additional","affiliation":[{"name":"European Vaccine Initiative (EVI), 69115 Heidelberg, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-5157","authenticated-orcid":false,"given":"Monika","family":"Slezak","sequence":"additional","affiliation":[{"name":"European Vaccine Initiative (EVI), 69115 Heidelberg, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4441-5000","authenticated-orcid":false,"given":"Frank A. W.","family":"Verreck","sequence":"additional","affiliation":[{"name":"Biomedical Primate Research Centre (BPRC), 2288 GJ Rijswijk, The Netherlands"}]},{"given":"Holger","family":"Spiegel","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Molecular Biology and Applied Ecology IME, 52074 Aachen, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2913-5254","authenticated-orcid":false,"given":"Carlos A.","family":"Guzman","sequence":"additional","affiliation":[{"name":"Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0414-4899","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Rold\u00e3o","sequence":"additional","affiliation":[{"name":"iBET\u2014Instituto de Biologia Experimental e Tecnol\u00f3gica, 2781-901 Oeiras, Portugal"}]},{"given":"Manuel J. T.","family":"Carrondo","sequence":"additional","affiliation":[{"name":"iBET\u2014Instituto de Biologia Experimental e Tecnol\u00f3gica, 2781-901 Oeiras, Portugal"}]},{"given":"Peter","family":"Van der Ley","sequence":"additional","affiliation":[{"name":"Intravacc BV, 3721 MA Bilthoven, The Netherlands"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1539-7261","authenticated-orcid":false,"given":"Joaquim","family":"Segal\u00e9s","sequence":"additional","affiliation":[{"name":"Unitat Mixta d\u2019Investigaci\u00f3 IRTA UAB en Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Departament de Sanitat i Anatomia Animals, Facultat de Veterin\u00e0ria, Campus de la Universitat Aut\u00f2noma de Barcelona, 08193 Bellaterra, Spain"}]},{"given":"Hazel M.","family":"Dockrell","sequence":"additional","affiliation":[{"name":"Department of Infection Biology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK"}]},{"given":"Mei Mei","family":"Ho","sequence":"additional","affiliation":[{"name":"Medicines and Healthcare Products Regulatory Agency (MHRA), Potters Bar EN6 3QG, UK"}]},{"given":"Gabriel K.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Immunology, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen, Denmark"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4762-9132","authenticated-orcid":false,"given":"Maria","family":"Lawrenz","sequence":"additional","affiliation":[{"name":"Vaccine Formulation Institute (VFI), Plan-les-Ouates, 1228 Geneva, Switzerland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3025-2466","authenticated-orcid":false,"given":"Ole F.","family":"Olesen","sequence":"additional","affiliation":[{"name":"European Vaccine Initiative (EVI), 69115 Heidelberg, Germany"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1016\/j.vaccine.2015.01.079","article-title":"TRANSVAC Research Infrastructure\u2013Results and Lessons Learned from the European Network of Vaccine Research and Development","volume":"33","author":"Geels","year":"2015","journal-title":"Vaccine"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biologicals.2022.02.003","article-title":"A Gaps-and-Needs Analysis of Vaccine R&D in Europe: Recommendations to Improve the Research Infrastructure","volume":"76","author":"Jungbluth","year":"2022","journal-title":"Biologicals"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-2600(24)00179-6","article-title":"Estimated Number of Lives Directly Saved by COVID-19 Vaccination Programmes in the WHO European Region from December, 2020, to March, 2023: A Retrospective Surveillance Study","volume":"12","author":"Brown","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_4","unstructured":"(2024, October 15). European Network of Vaccine Development and Research|TRANSVAC|Project|Fact Sheet|FP7|CORDIS|European Commission. Available online: https:\/\/cordis.europa.eu\/project\/id\/228403."},{"key":"ref_5","unstructured":"(2024, October 15). Vaccines Europe Pipeline Review 2023. Available online: https:\/\/www.vaccineseurope.eu\/wp-content\/uploads\/2023\/11\/VaccinesEurope-PipelineReview2023.pdf."},{"key":"ref_6","unstructured":"(2024, December 03). Vaccines Licensed for Use in the United States|FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic Cancer Vaccines: Advancements, Challenges, and Prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"A37","DOI":"10.1016\/j.vaccine.2011.04.125","article-title":"The Vaccine Formulation Laboratory: A Platform for Access to Adjuvants","volume":"29","author":"Collin","year":"2011","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Schmidt, S.T., Christensen, D., and Perrie, Y. (2020). Applying Microfluidics for the Production of the Cationic Liposome-Based Vaccine Adjuvant CAF09b. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12121237"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1016\/j.vaccine.2011.05.026","article-title":"Bis-(3\u2032,5\u2032)-Cyclic Dimeric Adenosine Monophosphate: Strong Th1\/Th2\/Th17 Promoting Mucosal Adjuvant","volume":"29","author":"Ebensen","year":"2011","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lirussi, D., Weissmann, S.F., Ebensen, T., Nitsche-Gloy, U., Franz, H.B.G., and Guzm\u00e1n, C.A. (2021). Cyclic Di-Adenosine Monophosphate: A Promising Adjuvant Candidate for the Development of Neonatal Vaccines. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13020188"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zariri, A., Pupo, E., Van Riet, E., Van Putten, J.P.M., and Van Der Ley, P. (2016). Modulating Endotoxin Activity by Combinatorial Bioengineering of Meningococcal Lipopolysaccharide. Sci. Rep., 6.","DOI":"10.1038\/srep36575"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100330","DOI":"10.1016\/j.jvacx.2023.100330","article-title":"Immune Responses Following Neonatal Vaccination with Conserved F4 Fragment of VtaA Proteins from Virulent Glaesserella Parasuis Adjuvanted with CAF\u00ae01 or CDA","volume":"14","author":"Mahmmod","year":"2023","journal-title":"Vaccine X"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Serrano, S., Cordoba, L., P\u00e9rez-Maillo, M., Pleguezuelos, P., Remarque, E.J., Ebensen, T., Guzm\u00e1n, C.A., Christensen, D., Segal\u00e9s, J., and Darji, A. (2021). Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF\u00ae01 or CDA\/AGalCerMPEG. Vaccines, 9.","DOI":"10.3390\/vaccines9070751"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jhep.2022.12.013","article-title":"Activation of CD4 T Cells during Prime Immunization Determines the Success of a Therapeutic Hepatitis B Vaccine in HBV-Carrier Mouse Models","volume":"78","author":"Su","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"110026","DOI":"10.1016\/j.virol.2024.110026","article-title":"Mucosal Vaccines for Viral Diseases: Status and Prospects","volume":"593","author":"Ma","year":"2024","journal-title":"Virology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Katsande, P.M., Fern\u00e1ndez-Bastit, L., Ferreira, W.T., Vergara-Alert, J., Hess, M., Lloyd-Jones, K., Hong, H.A., Segales, J., and Cutting, S.M. (2022). Heterologous Systemic Prime-Intranasal Boosting Using a Spore SARS-CoV-2 Vaccine Confers Mucosal Immunity and Cross-Reactive Antibodies in Mice as Well as Protection in Hamsters. Vaccines, 10.","DOI":"10.3390\/vaccines10111900"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sister\u00e9-Or\u00f3, M., L\u00f3pez-Serrano, S., Veljkovic, V., Pina-Pedrero, S., Vergara-Alert, J., C\u00f3rdoba, L., P\u00e9rez-Maillo, M., Pleguezuelos, P., Vidal, E., and Segal\u00e9s, J. (2019). DNA Vaccine Based on Conserved HA-Peptides Induces Strong Immune Response and Rapidly Clears Influenza Virus Infection from Vaccinated Pigs. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0222201"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100185","DOI":"10.1016\/j.xcrm.2020.100185","article-title":"Stronger Induction of Trained Immunity by Mucosal BCG or MTBVAC Vaccination Compared to Standard Intradermal Vaccination","volume":"2","author":"Vierboom","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_20","unstructured":"Stockhofe, N., and \u015al\u0119zak, M. (2024, November 15). Workshop on Mucosal Vaccines and Aerosol Use in Vaccine Development. Available online: https:\/\/cordis.europa.eu\/project\/id\/730964\/results."},{"key":"ref_21","unstructured":"iPROVE (2016). A Strategic European Roadmap for the Vaccines of Tomorrow: A Joint Stakeholder Reflection, iPROVE."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kaur, M., Coppeta, L., and Olesen, O.F. (2023). Vaccine Hesitancy among Healthcare Workers in Europe: A Systematic Review. Vaccines, 11.","DOI":"10.3390\/vaccines11111657"},{"key":"ref_23","unstructured":"Directorate-General for Health and Food Safety (2022). State of Vaccine Confidence in the EU, Directorate-General for Health and Food Safety."},{"key":"ref_24","unstructured":"(2024, September 20). VACCELERATE\u2013European Corona Vaccine Trial Accelerator Platform|VACCELERATE|Project|Fact Sheet|H2020|CORDIS|European Commission. Available online: https:\/\/cordis.europa.eu\/project\/id\/101037867."},{"key":"ref_25","unstructured":"(2024, April 29). Regulation\u20131394\/2007\u2013EN\u2013EUR-Lex. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/en\/ALL\/?uri=CELEX%3A32007R1394."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.12688\/f1000research.141399.1","article-title":"Potential Business Model for a European Vaccine R&D Infrastructure and Its Estimated Socio-Economic Impact","volume":"12","author":"Jungbluth","year":"2023","journal-title":"F1000Res"},{"key":"ref_27","unstructured":"Africa CDC (2022). Partnerships for African Vaccine Manufacturing (PAVM) Framework for Action, Africa CDC."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/12\/1446\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:57:59Z","timestamp":1760115479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/12\/1446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,22]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["vaccines12121446"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12121446","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2024,12,22]]}}}